US 11,957,691 B2
Drug for preventing and/or treating polycystic kidney disease
Hiroyuki Fujiki, Osaka (JP); Miki Aihara, Osaka (JP); and Shizuo Kinoshita, Osaka (JP)
Assigned to OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed by OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed on Sep. 15, 2021, as Appl. No. 17/475,451.
Application 17/475,451 is a division of application No. 16/225,255, filed on Dec. 19, 2018, granted, now 11,147,821.
Application 15/473,032 is a division of application No. 14/402,540, granted, now 9,636,382, issued on May 2, 2017, previously published as PCT/JP2013/065637, filed on May 30, 2013.
Application 16/225,255 is a continuation of application No. 15/473,032, filed on Mar. 29, 2017, abandoned.
Claims priority of provisional application 61/653,524, filed on May 31, 2012.
Prior Publication US 2022/0241293 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/55 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01); A61K 38/31 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/55 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 38/10 (2013.01); A61K 38/31 (2013.01); A61K 45/06 (2013.01)] 3 Claims
 
1. A combination for suppressing progression of polycystic kidney disease and/or treating polycystic kidney disease, wherein said combination comprises a synergistically effective amount of a sustained-release formulation of tolvaptan or a prodrug thereof, and a sustained-release formulation of vapreotide or a salt thereof.